Description

NODAGA-LM3 TFA is a specialized chelator-based peptide designed to facilitate molecular imaging and targeted research applications. It can be labeled with the radioisotope [68Ga], producing 68Ga-NODAGA-LM3 TFA, a potent SSTR2 antagonist. This makes it highly valuable for PET imaging studies, especially for visualizing SSTR-positive paragangliomas and related tumor models.

Researchers are increasingly utilizing NODAGA-LM3 TFA in the design and synthesis of Radionuclide-Drug Conjugates (RDCs), advancing the development of targeted therapeutic and diagnostic tools. Its ability to stably bind gallium-68 enhances both imaging clarity and tracer reliability.

Manufactured under GMP standards, NODAGA-LM3 TFA ensures reproducibility, purity, and consistency across research batches, supporting both academic laboratories and pharmaceutical R&D teams. This compound is intended solely for scientific and laboratory use, not for human or veterinary administration.

Product Specifications

Mechanism of Action & Research Applications

NODAGA-LM3 TFA functions as a chelating agent that binds effectively to gallium-68 (68Ga). When labeled, the compound produces 68Ga-NODAGA-LM3 TFA, which selectively acts as a somatostatin receptor type 2 (SSTR2) antagonist.

This receptor-specific interaction enables detailed PET imaging of SSTR2-positive tumors, including paragangliomas and other neuroendocrine malignancies. Compared to agonists, antagonists such as NODAGA-LM3 TFA often provide higher tumor uptake and clearer imaging, making it a powerful research tool in molecular oncology.

Additionally, its role in Radionuclide-Drug Conjugate (RDC) development positions it as an essential compound in translational research. RDCs represent a novel therapeutic avenue, combining targeted imaging with radionuclide-based therapies to potentially improve diagnostic accuracy and therapeutic efficacy in cancer research models.

Side Effects (For Reference in Models)

As a laboratory research compound, NODAGA-LM3 TFA has no direct clinical safety profile. However, potential observed side effects in research models may include:

• Alterations in receptor activity due to SSTR2 binding

• Possible biodistribution-related effects when conjugated with radionuclides

• Radiation exposure considerations when labeled with [68Ga]

All handling must follow laboratory safety standards, and appropriate protective measures should be used.

Disclaimer

 is supplied strictly for laboratory research use only. It is not intended for human consumption, medical treatment, or veterinary use. Wholesale and retail supply available.

Keywords

• SSTR2 antagonist imaging

• PET imaging research compound

• Radionuclide-drug conjugates RDC

• GMP peptide supplier

• NODAGA chelator peptide

• Neuroendocrine tumor imaging research

• Paraganglioma PET tracer

• Gallium-68 labeled peptide